A cohort study of the ocular safety of anti-ulcer drugs.
1996 (English)In: British Journal of Clinical Pharmacology, ISSN 0306-5251, E-ISSN 1365-2125, Vol. 42, no 2, 213-216 p.Article in journal (Refereed) Published
1. Recently, some cases have been reported where intravenous use of omeprazole was followed by loss of vision. We followed up a cohort of close to 140,000 persons during periods of treatment and non-treatment with five anti-ulcer drugs.
2. The relative risk of vascular disorders of the eye during use of omeprazole compared with non-use was 1.8 (95% CI 0.5-6.0). Use of other anti-ulcer drugs was associated with a similar risk of vascular disorders. The relative risk associated with current use of any anti-ulcer drug was 1.9 (95% CI 1.1-3.4). We did not find a single case of optic inflammatory disorder during treatment with any of the five anti-ulcer drugs.
3. These results do not suggest a major increased risk for vascular or inflammatory disorders of the eye associated with use of omeprazole or other anti-ulcer drugs.
Place, publisher, year, edition, pages
1996. Vol. 42, no 2, 213-216 p.
Omeprazole, anti-ulcer drugs, ocular safety
IdentifiersURN: urn:nbn:se:uu:diva-53548DOI: 10.1046/j.1365-2125.1996.40211.xISI: A1996VB50700011PubMedID: 8864320OAI: oai:DiVA.org:uu-53548DiVA: diva2:81458